

1 **Type of Issue** Initial Public Offer

2 **Issue Size (Rs. Mn)** 8,402.67

\*Source: Prospectus

3 **Grade of issue along with name of the rating agency**

**Name** NA  
**Grade** NA

4 **Subscription Level (Number of times)** 5.97\*

\* Figure is prior to rejections

Source: Minutes for basis of allotment dated October 30, 2023

5 **QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

| Particulars   | %age          |
|---|---------------|
| (i) On Allotment **   | 7.00%         |
| (ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2023) | 6.63%         |
| (iii) at the end of 1st FY (March 31, 2024)   | 5.04%         |
| (iv) at the end of 2nd FY (March 31, 2025)  | 3.62%         |
| (v) at the end of 3rd FY (March 31, 2026)*  | Not Available |

\*\*Basis of Allotment

^Holding of institutions category as disclosed to Stock Exchanges

\* QIB Holding not disclosed as reporting for relevant period has not been completed.

6 **Financials of the issuer**

(Rs. Million)

| Parameters                              | 1st FY<br>(March 31,2024) | 2nd FY<br>(March 31,2025) | 3rd FY<br>(March 31,2026)* |
|---|---------------------------|---------------------------|----------------------------|
| Income from operations                  | 7,115.98                  | 10,300                    | Not Available              |
| Net Profit for the period               | 1,637.51                  | 3,052                     | Not Available              |
| Paid-up equity share capital            | 346.93                    | 346.93                    | Not Available              |
| Reserves excluding revaluation reserves | 8,105.30                  | 10,984                    | Not Available              |

\* Financials not available as reporting for the relevant years has not been completed.

7 **Trading Status**

The equity shares of Bluejet Healthcare Limited were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") in November 2023

The equity shares have not been suspended or delisted.

| Particulars                                  | Status            |
|--|-------------------|
| (i) at the end of 1st FY (March 31, 2024)    | Frequently traded |
| (ii) at the end of 2nd FY (March 31, 2025)   | Frequently traded |
| (iii) at the end of 3rd FY (March 31, 2026)* | Not Available     |

\* Trading status not disclosed as the relevant fiscal year has not completed.

Source: Stock exchange data.

8 **Change in Directors of Issuer from the disclosures in the offer document**

| Particulars                                  | Name of Director                      | Appointed / Resigned   |
|--|---------------------------------------|------------------------|
| (i) at the end of 1st FY (March 31, 2024)    | -                                     | -                      |
| (ii) at the end of 2nd FY (March 31, 2025)   | Priyanka Yadav<br>Popat Bhagwan Kedar | Appointed<br>Appointed |
| (iii) at the end of 3rd FY (March 31, 2026)* | Not Available                         | Not Available          |

\* Changes in Directors of Issuer not updated as the reporting for the relevant financial years has not been completed

9 **Status of implementation of project/ commencement of commercial production**

(i) as disclosed in the offer document Not applicable as 100% offer for sale  
(ii) Actual implementation Not applicable  
(iii) Reasons for delay in implementation, if any Not applicable

10 **Status of utilization of issue proceeds**

(i) As disclosed in the offer document Not applicable as 100% offer for sale  
(ii) Actual utilization Not applicable  
(iii) Reasons for deviation, if any Not applicable

**11 Comments of monitoring agency, if applicable**

|  |                |
|--|----------------|
| (i) Comments on use of funds   | Not applicable |
| (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document | Not applicable |
| (iii) Any other reservations expressed by the monitoring agency about the end use of funds                             | Not applicable |

**12 Pricing Data**

|                           |          |
|---------------------------|----------|
| Designated Stock Exchange | NSE      |
| Issue Price (Rs.)         | 346.00   |
| Listing Date              | 1-Nov-23 |

| Price parameters | At close of listing day- November 1, 2023                                     | Close of 30th calendar day from listing day (i.e. Nov 30, 2023) | Close of 90th calendar day from listing day (i.e. Jan 29, 2024) | As at the end of the 1st FY after the listing of the issue (31st March, 2024)              |               |               |
|------------------|---|---|---|--|---------------|---------------|
|                  |   |   |   | Closing price  | High          | Low           |
| Market Price     | 413.4   | 360.1   | 381.0   | 382.9  | 384.7         | 371.1         |
| NIFTY 50*        | 18,989.2  | 20,133.2  | 21,737.6  | 22,326.9   | 22,516.00     | 22,163.60     |
| Price parameters | As at the end of the 2nd FY after the listing of the issue (31st March, 2025) |   |   | As at the end of the 3rd FY after the listing of the issue (31st March, 2026) <sup>1</sup> |               |               |
|                  | Closing price   | High  | Low   | Closing price  | High          | Low           |
| Market Price     | 884.9   | 904.0   | 874.8   | Not Available  | Not Available | Not Available |
| Nifty 50*        | 23,519.4  | 26,277.4  | 21,281.5  | Not Available  | Not Available | Not Available |

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal year has not completed

**13 Basis for Issue Price**

| Accounting ratio |              | As disclosed in offer document, at the end of FY 2023* | At the end of 1st FY (March 31, 2024) | At the end of 2nd FY (March 31, 2025) | At the end of 3rd FY (March 31, 2026)** |
|------------------|--------------|--|---------------------------------------|---------------------------------------|---|
| EPS (Diluted)    | Company      |  |                                       |                                       |   |
|                  | Consolidated | 9.23   | 9.44                                  | 17.59                                 | Not available                           |
|                  | Peer Group   | Not Applicable   | Not Applicable                        | Not Applicable                        | Not Applicable                          |
| P/E              | Company      |  |                                       |                                       |   |
|                  | Consolidated | 37.49  | 40.56                                 | 50.30                                 | Not available                           |
|                  | Peer Group   | Not Applicable   | Not Applicable                        | Not Applicable                        | Not Applicable                          |
| RoNW             | Company      |  |                                       |                                       |   |
|                  | Consolidated | 23.48%   | 19.37%                                | 26.93%                                | Not available                           |
|                  | Peer Group   | Not Applicable   | Not Applicable                        | Not Applicable                        | Not Applicable                          |
| NAV per share    | Company      |  |                                       |                                       |   |
|                  | Consolidated | 39.29  | 48.73                                 | 65.32                                 | Not available                           |
|                  | Peer Group   | Not Applicable   | Not Applicable                        | Not Applicable                        | Not Applicable                          |

Notes

\* Sourced from Prospectus dated October 27, 2023

\*\*The pricing data is not disclosed as the relevant fiscal year has not completed

**14 Any other material information**

| Particulars  | Date      |
|--|-----------|
| Company has informed that a fire incident occurred on the morning of 03rd November 2023 at Company's Mahad plant situated at K-4/1, Mahad Industrial area Mahad, Maharashtra .   | 3-Nov-23  |
| Company has informed that till date i.e November 5, 2023 there have been seven casualties and the Company's first priority as of now is to take care of the safety and well-being of the impacted employees and their family. Company team is working & co-operating with the state and local authorities to restore normalcy in the   | 5-Nov-23  |
| Company has informed that the Company has received an order by Maharashtra Pollution Control Board ("MPCB") vide letter dated November 7, 2023 issuing closure direction at one of our units at Mahad MIDC under Water (Prevention & Control Pollution) Act, 1974 and Air (Prevention & Control Pollution) Act, 1984.  | 9-Nov-23  |
| Company has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor   | 26-May-24 |
| Company has informed that in connection with the fire incident occurred on the morning of 03rd November 2023 at Company's Mahad plant situated at K-4/1, Mahad Industrial area Mahad, Maharashtra, Maharashtra Pollution Control Board has imposed environmental compensation of Rs. 3,91,875/-, forfeit of a bank guarantee of Rs. 5,00,000/- and a direction to submit the B.G of Rs. 10,00,000/- as preconditions to conditional restart of production. | 4-Sep-24  |

|   |           |
|---|-----------|
| Company has informed that they have received the consent dated 13 November, 2024 to operate under Section 26 of the Water (Prevention & Control of Pollution) Act, 1974 & under Section 21 of the Air (Prevention & Control of Pollution) Act, 1981 and Authorization under Rule 6 and Rule 18(7) of the Hazardous & Other Wastes (Management & Transboundary Movement) Rules 2016 for Company's Unit no3 at Mahad, Maharashtra.  | 15-Nov-24 |
| Company has informed the Exchange about Change in Directors   | 19-Nov-24 |
| Company has informed that Blue Jet Healthcare Limited at the Company's existing Unit 2 facility situated at Ambernath, Maharashtra, India, has successfully completed commissioning of production block to manufacture Advance Contrast Media on December 9, 2024   | 10-Dec-24 |
| The Board has approved investments of upto Rs 40 Crores for setting up of Research and Development Facility   | 29-Jan-25 |
| The Company notified the exchange about receipt of assessment orders and demand notices from the Income Tax Department under Section 156 of the Income Tax Act, 1961 ('the Act') essentially on account of disallowance of depreciation on goodwill in the Assessment year 2020-21 and disallowance of subsequent set-off of unabsorbed depreciation allowance. In this regard, the Company has filed an appeal before the Joint Commissioner (Appeals) /Commissioner of Income-tax (Appeals) Mumbai for the AYs 2020-21, 2021-22 & 2022-23 on March 31, 2025, pertaining to above demand.  | 1-Apr-25  |
| The Board of Directors approved the following -<br>a final dividend of Rupees 1.2 (60%) per Equity Share of the face value of Rs.2 each (Rupees Two only) for the Financial Year ended March 31, 2025. The Final Dividend is subject to the approval of the members at the ensuing Annual General Meeting which will be held within stipulated timeline as per the provisions of the Companies Act, 2013.<br>Proposal for raising of funds of up to ₹15,000 million by way of creation, offering and issuance of any instrument or security for cash, with or without green shoe option, including fully paid-up Equity Shares, fully or partly convertible debentures, any other equity based instruments or securities, convertible preference shares of any kind or type, any other financial instruments/ securities convertible into and/or linked to Equity Shares (including warrants (detachable or not), or otherwise, in registered or bearer form) (collectively "Securities") or combination of any of the aforementioned Securities<br>Appointment of Ms. Payal Gandhi, Chief Business Strategy Officer as Senior Management Personnel of the Company w.e.f. June 1, 2025.<br>Acquisition of a plot located at Dahej III, Industrial Estate Gujarat, measuring 30,366.32 square meters from the Gujarat Industrial Development Corporation (GIDC), for manufacturing purpose, in line with the business objectives of the company. The Agreement will be executed in due course. | 14-May-25 |
| To consider and approve raising of funds in one or more tranches, by issuance of Equity Shares and/or other Eligible Securities   | 16-Jun-25 |
| Approved the proposal for acquisition of an industrial land parcel and related investment at the new manufacturing site.  | 31-Jul-25 |

Soure: NSE and BSE website

**Note:** The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com).